29 November 2022 in International Journal of Gynecological Cancer
Advanced ovarian cancer remains a leading cause of death from gynecologic malignancy. Surgery and, in most cases, platinum-based chemotherapy with or without maintenance with bevacizumab and/or poly-ADP ribose polymerase inhibitors (PARPi) represent the mainstay of treatment, but the disease typically recurs. The treatment of these patients represents a clinical challenge because sequential chemotherapy regimens are often used, with suboptimal outcomes and cumulative toxicity. Chemotherapy-free regimens, based on combinations of PARPi, vascular endothelial growth factor receptor inhibitors, anti-programmed cell death protein-1/programmed death-ligand 1, and anti-cytotoxic T-lymphocyte-associated protein-4 antibodies, among others, represent a valid option, with manageable toxicity profile and ease of administration. This review addresses this new strategy in the management of recurrent ovarian cancer and discusses its feasibility in the treatment landscape of the disease.
29 December 2023 in Gazeta Médica
Endometriosis is a chronic inflammatory disease caused by the presence of extra-uterine endometrial tissue that affects women of reproductive age. Although the etiology remains not totally elucidated, recent advances in molecular technology, especially the ability for whole genome sequencing, have gradually revealed both genetic and epigenetic backgrounds for the development of the disease. Endometriosis has been recognized as a precursor lesion for certain types of ovarian cancer (endometriosis-associated ovarian cancers - EAOC) and the knowledge of this malignant potential is of paramount importance to seek for predictive factors and to select patients at risk. We report five different EAOC cases in our recent clinical practice, in order to draw attention to this issue through a literature review, and to provide clinicians with tools to communicate accurately and effectively with patients with endometriosis about their risk of ovarian cancer.